Predictors of extensively drug-resistant pulmonary tuberculosis

Annals of Internal Medicine

Volumn 150, Issue 11, 2009, Pages 766-775

  Kliiman, Kai ^a   Altraja, Alan ^a  

^a UNIVERSITY OF TARTU   (Estonia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ALCOHOL ABUSE; ALCOHOLISM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BIRTHPLACE; CROSS-SECTIONAL STUDY; DRUG RESISTANT TUBERCULOSIS; ESTONIA; FEMALE; HOMELESSNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMIGRANT; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING TEST; SEX DIFFERENCE; SOCIOECONOMICS; DRUG EFFECT; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; LUNG TUBERCULOSIS; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDY; RISK; RISK FACTOR;

ADULT; ALCOHOLISM; ANTITUBERCULAR AGENTS; CROSS-SECTIONAL STUDIES; ESTONIA; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HIV INFECTIONS; HOMELESS PERSONS; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; ODDS RATIO; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 66649118130     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-150-11-200906020-00004     Document Type: Article

References (30)

1. Migliori GB, Ortmann J, Girardi E, Besozzi G, Lange C, Cirillo DM, et al; SMIRA/TBNET Study Group. Extensively drug-resistant tuberculosis, Italy and Germany [Letter]. Emerg Infect Dis. 2007;13:780-782 [PMID: 18044040]
2. Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis. 2007;45:1290-1295 [PMID: 17968823]
3. Migliori GB, Besozzi G, Girardi E, Kliiman K, Lange C, Toungoussova OS, et al; SMIRA/TBNET Study Group. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J. 2007;30:623-626 [PMID: 17690121]
4. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575-1580 [PMID: 17084757] (Pubitemid 44780738)
5. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec. 2006;81:430-432 [PMID: 17096498]
6. Migliori GB, Loddenkemper R, Blasi F, Raviglione MC. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic? [Editorial]. Eur Respir J. 2007;29:423-427 [PMID: 17329486]
7. World Health Organization. Anti-tuberculosis drug resistance in the world. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Report no. 4. WHO/TB/2008.394. Geneva: World Health Organization; 2008.
8. World Health Organization. Global map and information on XDR-TB. Accessed at www.who.int/tb/challenges/xdr/en/index.html on 6 January 2009.
9. Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep. 2006;55:301-305 [PMID: 16557213]
10. Shah NS, Wright A, Bai GH, Barrera L, Boulahbal F, Martín-Casabona N, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis. 2007;13:380-387 [PMID: 17552090] (Pubitemid 46348124)
11. Becerra MC, Bayona J, Freeman J, Farmer PE, Kim JY. Redefining MDR-TB transmission 'hot spots'. Int J Tuberc Lung Dis. 2000;4:387-394 [PMID: 10815730]
12. Hollo V. Tuberculosis Incidence in Estonia 2005. Tallinn: National Institute for Health Development; 2007.
13. UNAIDS/WHO. AIDS Epidemic Update: December 2006. Accessed at data.unaids.org/pub/EpiReport/2006/2006-EpiUpdate-en.pdf on 16 September 2008.
14. Jeon CY, Hwang SH, Min JH, Prevots DR, Goldfeder LC, Lee H, et al. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis. 2008;46:42-49 [PMID: 18171212]
15. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, et al. Speaking the same language: treatment outcome definitions for multidrugresistant tuberculosis. Int J Tuberc Lung Dis. 2005;9:640-645 [PMID: 15971391] (Pubitemid 40826156)
16. World Health Organization. Alcohol use and abuse. What you should know. World Health Organization, Regional Office for Southeast Asia. Alcohol Control Series no. 4. Geneva: World Health Organization; 2006.
17. Laszlo A, Rahman M, Espinal M, Raviglione M; WHO/IUATLD Network of Supranational Reference Laboratories. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Reference Laboratory Network: five rounds of proficiency testing, 1994- 1998. Int J Tuberc Lung Dis. 2002;6:748-756 [PMID: 12234129]
18. Casal M, Vaquero M, Rinder H, Tortoli E, Grosset J, Rüsch-Gerdes S, et al. A case-control study for multidrug-resistant tuberculosis: risk factors in four European countries. Microb Drug Resist. 2005;11:62-67 [PMID: 15770097] (Pubitemid 40365847)
19. Falzon D, Infuso A, Aït-Belghiti F. In the European Union, TB patients from former Soviet countries have a high risk of multidrug resistance. Int J Tuberc Lung Dis. 2006;10:954-958 [PMID: 16964783]
20. Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax. 2006;61:158-163 [PMID: 16254056] (Pubitemid 43235434)
21. Granich RM, Oh P, Lewis B, Porco TC, Flood J. Multidrug resistance among persons with tuberculosis in California, 1994-2003. JAMA. 2005;293:2732-2739 [PMID: 15941802]
22. Mdivani N, Zangaladze E, Volkova N, Kourbatova E, Jibuti T, Shubladze N, et al. High prevalence of multidrug-resistant tuberculosis in Georgia. Int J Infect Dis. 2008;12:635-644 [PMID: 18514008]
23. Mukherjee JS, Rich ML, Socci AR, Joseph JK, Virú FA, Shin SS, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet. 2004;363:474-481 [PMID: 14962530] (Pubitemid 38210067)
24. Clark CM, Li J, Driver CR, Munsiff SS. Risk factors for drug-resistant tuberculosis among non-US-born persons in New York City. Int J Tuberc Lung Dis. 2005;9:964-969 [PMID: 16158888] (Pubitemid 41549182)
25. Lockman S, Kruuner A, Binkin N, Levina K, Wang Y, Danilovitsh M, et al. Clinical outcomes of Estonian patients with primary multidrug-resistant versus drug-susceptible tuberculosis. Clin Infect Dis. 2001;32:373-380 [PMID: 11170944] (Pubitemid 32173622)
26. Härö AS. Cohort approach in tuberculosis surveillance: comparison of the situation in Sweden and Finland. Tuber Lung Dis. 1994;75:271-282 [PMID: 7949073] (Pubitemid 24270992)
27. Tekkel M, Rahu M, Loit HM, Baburin A. Risk factors for pulmonary tuberculosis in Estonia. Int J Tuberc Lung Dis. 2002;6:887-894 [PMID: 12365575] (Pubitemid 35190702)
28. Jakubowiak WM, Bogorodskaya EM, Borisov SE, Borisov ES, Danilova ID, Danilova DI, et al. Risk factors associated with default among new pulmonary TB patients and social support in six Russian regions. Int J Tuberc Lung Dis. 2007;11:46-53. [PMID: 17217129] (Pubitemid 46101845)
29. Ruddy M, Balabanova Y, Graham C, Fedorin I, Malomanova N, Elisarova E, et al. Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia. Thorax. 2005;60:130-135 [PMID: 15681501]
30. Coker R, McKee M, Atun R, Dimitrova B, Dodonova E, Kuznetsov S, et al. Risk factors for pulmonary tuberculosis in Russia: case-control study. BMJ. 2006;332:85-87 [PMID: 16339219] (Pubitemid 43099249)